[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2021007706A - Conjugados de agonistas de receptor de reconocimiento de patron. - Google Patents

Conjugados de agonistas de receptor de reconocimiento de patron.

Info

Publication number
MX2021007706A
MX2021007706A MX2021007706A MX2021007706A MX2021007706A MX 2021007706 A MX2021007706 A MX 2021007706A MX 2021007706 A MX2021007706 A MX 2021007706A MX 2021007706 A MX2021007706 A MX 2021007706A MX 2021007706 A MX2021007706 A MX 2021007706A
Authority
MX
Mexico
Prior art keywords
pattern recognition
conjugate
individually
recognition receptor
conjugates
Prior art date
Application number
MX2021007706A
Other languages
English (en)
Inventor
Nicola Bisek
Tobias Voigt
Samuel Weisbrod
Sebastian Stark
Torben Lessmann
Kennett Sprogøe
Yang Yang-Malten
Original Assignee
Ascendis Pharma Oncology Div A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma Oncology Div A/S filed Critical Ascendis Pharma Oncology Div A/S
Publication of MX2021007706A publication Critical patent/MX2021007706A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se relaciona con un conjugado o su sal farmacéuticamente aceptable, en donde el conjugado es insoluble en agua y comprende una porción portadora Z a la cual una o más porciones -L2-L1-D están conjugadas, en donde cada -L2- es individualmente una conexión química o una porción separadora; cada -L1- es individualmente una porción enlazadora a la cual -D está conjugado de manera reversible y covalente; y cada -D es un agonista de receptor de reconocimiento de patrón. Se relaciona adicionalmente con composiciones farmacéuticas que comprenden estos conjugados y su uso en el tratamiento de trastornos de proliferación celular; y con aspectos relacionados.
MX2021007706A 2019-01-04 2020-01-03 Conjugados de agonistas de receptor de reconocimiento de patron. MX2021007706A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP19150384 2019-01-04
EP19181817 2019-06-21
EP19206474 2019-10-31
PCT/EP2020/050093 WO2020141221A1 (en) 2019-01-04 2020-01-03 Conjugates of pattern recognition receptor agonists

Publications (1)

Publication Number Publication Date
MX2021007706A true MX2021007706A (es) 2021-08-05

Family

ID=69105885

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007706A MX2021007706A (es) 2019-01-04 2020-01-03 Conjugados de agonistas de receptor de reconocimiento de patron.

Country Status (12)

Country Link
US (1) US20220062273A1 (es)
EP (1) EP3906060A1 (es)
JP (1) JP2022516308A (es)
KR (1) KR20210113262A (es)
CN (1) CN113557033A (es)
AU (1) AU2020204970A1 (es)
BR (1) BR112021011592A2 (es)
CA (1) CA3125533A1 (es)
IL (1) IL284449A (es)
MX (1) MX2021007706A (es)
SG (1) SG11202105835YA (es)
WO (1) WO2020141221A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109843327B (zh) 2016-07-07 2022-05-13 小利兰·斯坦福大学托管委员会 抗体佐剂缀合物
US20220054478A1 (en) * 2019-01-04 2022-02-24 Ascendis Pharma Oncology Division A/S Minimization of systemic inflammation
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
EP4161956A1 (en) 2020-06-03 2023-04-12 Ascendis Pharma Oncology Division A/S Il-2 sequences and uses thereof
AU2021335032A1 (en) 2020-08-28 2023-03-09 Ascendis Pharma Oncology Division A/S Glycosylated IL-2 proteins and uses thereof
AU2022409306A1 (en) 2021-12-13 2024-06-06 Ascendis Pharma Oncology Division A/S Cancer treatments with tlr7/8 agonists

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US7332164B2 (en) 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
WO2004089280A2 (en) 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
US7690003B2 (en) 2003-08-29 2010-03-30 Fuller Jeffrey C System and method for increasing data throughput using thread scheduling
CA2940803A1 (en) 2004-03-23 2005-10-27 Ascendis Pharma Gmbh Prodrug linker
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
EP2063709A2 (en) 2006-09-15 2009-06-03 Enzon Pharmaceuticals, Inc. Hindered ester-based biodegradable linkers for oligonucleotide delivery
EP2175878A4 (en) 2007-07-11 2014-12-03 Belrose Pharma Inc POLYMER DRUG DISPENSING SYSTEM WITH A MULTIPLE SUBSTITUTED AROMATIC PART
RU2010136023A (ru) 2008-02-01 2012-03-10 Асцендис Фарма Ас (Dk) Пролекарство, содержащее саморасщепляемый линкер
JP2011520983A (ja) 2008-05-23 2011-07-21 エンゾン ファーマシューティカルズ，インコーポレーテッド オリゴヌクレオチドの送達のための細胞内遊離可能ジスルフィドリンカーを含有するポリマーシステム
WO2010138192A2 (en) * 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Nanocarriers possessing components with different rates of release
BR112012002280B1 (pt) * 2009-07-31 2020-04-07 Ascendis Pharma As hidrogel insolúvel em água baseado em polietileno glicol biodegradável, seu processo de preparação, conjugado, composto ligado a veículo e composição farmacêutica.
US9173953B2 (en) 2009-07-31 2015-11-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
EP2519228A4 (en) 2009-12-31 2013-06-19 Enzon Pharmaceuticals Inc POLYMER CONJUGATES FROM AN AROMATIC AMINE WITH COMPOUNDS WITH A CLEANER UREA CONTAINER
EP2525829A1 (en) 2010-01-22 2012-11-28 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aromatic amine-containing drugs
WO2011089214A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Carrier-linked carbamate prodrug linkers
WO2011089216A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
CN103025165B (zh) 2010-05-05 2016-06-08 普罗林科斯有限责任公司 自大分子共轭物的控释
JP5964815B2 (ja) 2010-05-05 2016-08-03 プロリンクス リミテッド ライアビリティ カンパニー 固体担体からの放出制御薬物
CA2843506C (en) 2011-08-12 2020-05-12 Ascendis Pharma A/S Carrier-linked prodrugs having reversible carboxylic ester linkages
WO2013024052A1 (en) 2011-08-12 2013-02-21 Ascendis Pharma A/S Carrier-linked treprostinil prodrugs
WO2013036857A1 (en) 2011-09-07 2013-03-14 Prolynx Llc Sulfone linkers
US20150010634A1 (en) * 2011-10-12 2015-01-08 Ascendis Pharma Ophthamology Division A/S Prevention and treatment of ocular conditions
WO2013160340A1 (en) 2012-04-25 2013-10-31 Ascendis Pharma A/S Prodrugs of hydroxyl-comprising drugs
CN104781314B (zh) 2012-10-11 2017-11-14 阿森迪斯药物股份有限公司 水凝胶前药
US11633487B2 (en) 2014-08-06 2023-04-25 Ascendis Pharma A/S Prodrugs comprising an aminoalkyl glycine linker
HUE053855T2 (hu) 2014-11-18 2021-07-28 Ascendis Pharma Endocrinology Div A/S Új polimer hGH prodrogok
JP7216006B2 (ja) 2017-03-22 2023-01-31 ジェネンテック， インコーポレイテッド ヒドロゲル架橋ヒアルロン酸プロドラッグ組成物及び方法
EP3628010A4 (en) * 2017-05-02 2021-02-17 Nektar Therapeutics IMMUNOTHERAPEUTIC TUMOR TREATMENT PROCEDURE
KR20200139730A (ko) 2018-03-28 2020-12-14 아센디스 파마 온콜로지 디비전 에이/에스 Il-2 접합체

Also Published As

Publication number Publication date
US20220062273A1 (en) 2022-03-03
EP3906060A1 (en) 2021-11-10
WO2020141221A1 (en) 2020-07-09
TW202042844A (zh) 2020-12-01
AU2020204970A1 (en) 2021-06-24
CN113557033A (zh) 2021-10-26
JP2022516308A (ja) 2022-02-25
SG11202105835YA (en) 2021-07-29
IL284449A (en) 2021-08-31
CA3125533A1 (en) 2020-07-09
BR112021011592A2 (pt) 2021-10-26
KR20210113262A (ko) 2021-09-15

Similar Documents

Publication Publication Date Title
MX2021007706A (es) Conjugados de agonistas de receptor de reconocimiento de patron.
WO2015155753A3 (en) Novel linkers and their uses in specific conjugation of drugs to biological molecule
MY195368A (en) A Conjugation Linker Containing 2,3-Diaminosuccinyl Group
CY1112278T1 (el) Κυτταροτοξικοι παραγοντες που περιεχουν νεα παραγωγα τομαυμυciν και η θεραπευτικη χρηση τους
EP4316524A3 (en) Camptothecin derivatives
ES2638871T3 (es) Polipéptidos clorotoxina y conjugados y usos de los mismos
WO2020126609A3 (en) Antibody drug conjugates (adc) containing saponin
MY196189A (en) Cross-Linked Pyrrolobenzodiazepine Dimer (Pbd) Derivative and Its Conjugates
MX2020006482A (es) Ligandos de peptidos biciclicos especificos para el receptor eph de tirosina quinasa a2 (epha2).
MY195114A (en) Specific Conjugation Linkers, Specific Immunoconjugates Thereof, Methods of Making and uses Such Conjugates Thereof
MX2010005813A (es) Conjugados oligomero-triciclicos.
MX2009009851A (es) Conjugados de agonistas de oligomeros-opioides.
WO2015151081A3 (en) Bridge linkers for conjugation of cell-binding molecules
NZ744936A (en) Derivatives of amanita toxins and their conjugation to a cell binding molecule
NZ754810A (en) Pyrrolobenzodiazepine-antibody conjugates
MX2018008061A (es) Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes.
TW200500069A (en) Vitamin-receptor binding drug delivery conjugates
MX2023001588A (es) Conjugados biciclo específicos para nectina-4 y usos de estos.
SA521421855B1 (ar) مترافقات عقار-جسم مضاد
MX2021010003A (es) Anticuerpos anti-mertk de alta afinidad y usos de los mismos.
MX2022000037A (es) Enlazadores hidrofilicos para conjugados de peptidos multivalentes.
CY1113275T1 (el) Προϊοντα συζευξης για την θεραπεια μεσοθηλιωματος
WO2022194988A3 (en) B-lymphocyte specific amatoxin antibody conjugates
WO2005002516A3 (en) Leukocyte internalized peptide-drug conjugates
EA202191874A1 (ru) Конъюгаты агонистов паттерн-распознающего рецептора